Effective October 30, 2014, Transcept Pharmaceuticals, Inc. and Paratek Pharmaceuticals, Inc. closed a merger that resulted in a change in the name of Transcept Pharmaceuticals to Paratek Pharmaceuticals. The ticker symbol for Transcept has also changed from 'TSPT' to 'PRTK'.

Paratek is a pharmaceuticals company focused on the discovery, development, and commercialization of medicines designed to save lives and alleviate suffering. Our lead product candidate, omadacycline, is a new tetracycline-derived, broad-spectrum antibiotic being developed as a first-line monotherapy for serious community-acquired bacterial infections where antibiotic resistance is of concern.

Latest News

Special Cash Dividend

On October 14, 2014 Transcept Pharmaceuticals declared a special cash dividend, in connection with its merger with Paratek Pharmaceuticals.